Induced Abortion and the Risk of Rh Sensitization.

Importance While population-level data suggest Rh immunoglobulin is unnecessary before 12 weeks' gestation, clinical evidence is limited. Thus, guidelines vary, creating confusion surrounding risks and benefits of Rh testing and treatment. As abortion care in traditional clinical settings becomes harder to access, many people are choosing to self-manage and need to know if ancillary blood type testing is necessary. Objective To determine how frequently maternal exposure to fetal red blood cells (fRBCs) exceeds the most conservative published threshold for Rh sensitization in induced first-trimester abortion. Design, Setting, and Participants Multicenter, observational, prospective cohort study using high-throughput flow cytometry to detect circulating fRBCs in paired maternal blood samples before and after induced first-trimester abortion (medication or procedural). Individuals undergoing induced first-trimester abortion before 12 weeks 0 days' gestation were included. Paired blood samples were available from 506 participants who underwent either medical (n = 319 [63.0%]) or procedural (n = 187 [37.0%]) abortion. Exposure Induced first-trimester abortion. Main Outcomes and Measures The primary outcome was the proportion of participants with fRBC counts above the sensitization threshold (125 fRBCs/5 million total RBCs) after induced first-trimester abortion. Results Among the 506 participants, the mean (SD) age was 27.4 (5.5) years, 313 (61.9%) were Black, and 123 (24.3%) were White. Three of the 506 participants had elevated fRBC counts at baseline; 1 of these patients had an elevated fRBC count following the abortion (0.2% [95% CI, 0%-0.93%]). No other participants had elevated fRBC counts above the sensitization threshold after induced first-trimester abortion. The median change from baseline was 0 fRBCs, with upper 95th and 99th percentiles of 24 and 35.6 fRBCs, respectively. Although there was a strong association between the preabortion and postabortion fRBC counts, no other baseline characteristic was significantly associated with postabortion fRBC count. Conclusions and Relevance Induced first-trimester abortion is not a risk factor for Rh sensitization, indicating that Rh testing and treatment are unnecessary before 12 weeks' gestation. This evidence may be used to inform international guidelines for Rh immunoglobulin administration following first-trimester induced abortion.

[1]  D. Subtil,et al.  Anti‐RH1 alloimmunization: At what maternal antibody threshold is there a risk of severe fetal anemia? , 2023, Transfusion.

[2]  J. Holcomb,et al.  Not as “D”eadly as once thought – the risk of D-alloimmunization and hemolytic disease of the fetus and newborn following RhD-positive transfusion in trauma , 2023, Hematology.

[3]  A. Lazarus,et al.  Antigen‐specific IgG subclass composition in recipient mice can indicate the degree of red blood cell alloimmunization as well as discern between primary and secondary immunization , 2023, Transfusion.

[4]  S. Prager,et al.  Society of Family Planning committee consensus on Rh testing in early pregnancy. , 2022, Contraception.

[5]  D’AvenaAyesha,et al.  Normalizing High-Value Care: Findings of the National Quality Task Force , 2020 .

[6]  M. Sammel,et al.  The concentration of fetal red blood cells in first-trimester pregnant women undergoing uterine aspiration is below the calculated threshold for Rh sensitization. , 2020, Contraception.

[7]  A. Albert,et al.  Can we safely stop testing for Rh status and immunizing Rh-negative women having early abortions? A comparison of Rh alloimmunization in Canada and the Netherlands , 2018, Contraception: X.

[8]  S. Chauhan,et al.  Prevention of RhD Alloimmunization: A Comparison of Four National Guidelines , 2017, American Journal of Perinatology.

[9]  C. Arias,et al.  How do red blood cells know when to die? , 2017, Royal Society Open Science.

[10]  N. S. Nair,et al.  Anti-D administration after spontaneous miscarriage for preventing Rhesus alloimmunisation. , 2013, The Cochrane database of systematic reviews.

[11]  E. Elm,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[12]  S. Urbaniak The scientific basis of antenatal prophylaxis , 1998, British journal of obstetrics and gynaecology.

[13]  A. Zipursky,et al.  THE TRANSPLACENTAL PASSAGE OF FOETAL RED BLOOD-CELLS AND THE PATHOGENESIS OF RH IMMUNISATION DURING PREGNANCY. , 1963, Lancet.

[14]  Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. , 2017, Obstetrics and gynecology.

[15]  R. Visscher,et al.  Do Rh-negative women with an early spontaneous abortion need Rh immune prophylaxis? , 1972, American journal of obstetrics and gynecology.